|1.||Del Pup, Lino: 2 articles (11/2013 - 09/2012)|
|2.||Cavaliere, Carla: 1 article (11/2013)|
|3.||Facchini, Gaetano: 1 article (11/2013)|
|4.||Berretta, Massimiliano: 1 article (11/2013)|
|5.||Di Francia, Raffaele: 1 article (11/2013)|
|6.||Giorda, Giorgio: 1 article (11/2013)|
|7.||De Paoli, Paolo: 1 article (11/2013)|
|8.||Postruznik, D: 1 article (05/2012)|
|9.||Del Pup, L: 1 article (05/2012)|
|10.||Corona, G: 1 article (05/2012)|
08/01/2009 - "To investigate the safety and efficacy of promestriene capsule used in the treatment of postmenopausal atrophic vaginitis. "
08/01/2009 - "[Safety of promestriene capsule used in postmenopausal atrophic vaginitis]."
04/01/1985 - "[Therapeutic trial of the combination promestriene-chlorquinaldol in the treatment of vaginitis]."
|2.||Stress Urinary Incontinence
01/01/2007 - "Presurgical promestriene therapy in postmenopausal women with stress urinary incontinence."
01/01/2007 - "Our study was aimed at evaluating the efficacy of therapy with promestriene, a synthetic diethyl-ether of estradiol with no distal hormonal effects, in patients undergoing surgical correction for stress urinary incontinence (SUI). "
09/01/2012 - "Promestriene only possesses an intramucosal effect, it can be used at very low doses in cancer patients suffering from urogenital symptoms."
12/01/1982 - "This discrepancy between the local anti-atrophic effects and the inability to exert systemic oestrogen activities singles out promestriene and justifies its therapeutic use when hormonally active oestrogens are contra-indicated, as in patients who have an oestrogen-sensitive cancer in their medical history."
05/01/2012 - "Vaginal promestriene was tested in gynecological cancer patients who suffered from severe vaginal dryness and dyspareunia. "
11/01/2013 - "To further improve promestriene safety, especially in estrogen-sensitive cancer patients, a very low dose is used from the beginning, starting from half or less of the usual dose, and then gradually increased till the minimum effective dose, which could further reduce its already minimal vaginal absorption. "
05/01/2012 - "In highly symptomatic gynecological cancer patients the level of circulating estrone sulfate was not significantly affected by vaginal promestriene treatment overall, but a wide range of levels was noted pre and post treatment in individual patients."
|2.||Ethyl Ether (Ether)
|5.||estrone sulfate (Evex)